Difference between revisions of "Part:BBa K3182104"

 
(46 intermediate revisions by 4 users not shown)
Line 1: Line 1:
 +
<!-- -->
 
__TOC__
 
__TOC__
  
Line 5: Line 6:
 
<br>
 
<br>
 
<h1>Introduction</h1>
 
<h1>Introduction</h1>
 +
[[File:T--Linkoping_Sweden--fusionproteinillustration.jpg|420px|thumb|right|<b>Figure 1.</b> Mechanism of action for Novosite. The CBD<sub>cipA</sub>-fusion is attached to a polysaccaride material. By adding thrombin from any source the fusion protein will be cleaved and the C-terminal fusion protein will be released into the solution. By changing the fusion protein to an antimicrobial peptide/enzyme, and using the material as a bandage, the peptide/enzyme can be released into a wound by native human thrombin.]]
  
<partinfo>BBa_K3182104 short</partinfo>
+
This part consists of a carbohydrate binding domain (CBD) from <i>Clostridium thermocellum (C. thermocellum)</i> cellulose scaffolding protein (CipA). This binding domain is a central part of <i>Clostridium thermocellum's</i> cellusome and has a strong affinity for cellulose. The CBD was fused to another protein using a flexible GS-linker (-GGGGSGGGGS-) in order to attach this complex to a polysaccaride material. A thrombin cleavage site (-LVPRGS-) was added to the end of the linker and its breakage will leave a glycine and serine attached to the N-terminal of the fusion protein. The main mechanism of iGEM19 Linköping's project can be seen in Figure 1.
[[File:T--Linkoping_Sweden--fusionproteinillustration.jpg|420px|thumb|right|<b>Figure 1.</b> Mechanism of action. The CBDcipA-fusion is attached to cellulose. By adding thrombin from any source the fusion protein will be cleaved and the C-terminal fusion protein will be released into the solution. By changing the fusion protein to an antimicrobial peptide/enzyme, and using the cellulose as a bandage, the peptide/enzyme can be released into a wound by native human thrombin.]]
+
  
This part consists of a carbohydrate binding domain (CBD) from Clostridium thermocellum (C. thermocellum) cellulose scaffolding protein (CipA) and is a central part Clostridium thermocellum's cellusome. The CBD-fusion were fused using a flexible GS-linker (-GGGGSGGGGS-). A thrombin cleavage site (-LVPRGS-) was added to the end of the linker and its breakage will leave a glycine and serine attached to the N-terminal of the fusion protein.  
+
<h3>Protease site and use</h3>
 +
The thrombin site was added to enable the ability to release the fusion protein down into skin wounds. Thanks to our integrated human practice we learned that infections span much deeper into wounds that we thought. Simply attaching the CBD-fusion protein to a carbohydrate material would not enable the fusion protein to reach far into the wound. The thrombin site was also chosen because of thrombin's endogenous existence in humans.
  
 
<h3>Assembly compabilities</h3>
 
<h3>Assembly compabilities</h3>
An internal BamHI recognition sequence (RS) has been added to enable changeable fusion proteins. BamHI was chosen because its RS codes for glycine and serine, fitting it to the end of the thrombin site. It is also cost-effective enzyme and is unaffected by methylated DNA.
+
An internal BamHI recognition sequence (RS) has been added to enable interchangeable fusion proteins to the CBD. BamHI was chosen because its RS codes for glycine and serine, fitting it to the end of the thrombin site. It is also a cost-effective enzyme and is unaffected by methylated DNA. BamHI is a part of the RFC21 standard.
  
This part can be used to track purification, measure CBD binding ability and report cleavage at the thrombin site.
+
<br>
 
+
<br><br><br><br><br><br><br><br><br>
+
  
<h2>CBDcipA crystal structure</h2>
+
<h2>CBD<sub>cipA</sub> crystal structure</h2>
  
[[File:T--Linkoping_Sweden--rotatingcbdanimationloop.gif|420px|thumb|left|<b>Figure 1.</b> Crystal structure of CBDcipA with a resolution of 1.75 Å which were solved by [http://www.ncbi.nlm.nih.gov/pmc/PMC452321 Tormo et al. 1989]. PDB code 1NBC. In red from the left, W118, R112, D56, H57 and Y67, thought to be the surface which interacts strongly with cellulose.]]
+
[[File:T--Linkoping_Sweden--rotatingcbdanimationloop.gif|420px|thumb|left|<b>Figure 2.</b> Crystal structure of CBD<sub>cipA</sub> with a resolution of 1.75 Å which were solved by [http://www.ncbi.nlm.nih.gov/pmc/PMC452321 Tormo et al. 1989]. PDB code 1NBC. In red from the left, W118, R112, D56, H57 and Y67, thought to be the surface which interacts strongly with polysaccarides.]]
  
 
<h3>Important molecular faces</h3>
 
<h3>Important molecular faces</h3>
CBDcipA is composed of a nine-stranded beta sandwich with a jelly roll topology and binds a calcium ion. It further contains conserved residues exposed on the surface which map into two clear surfaces on each side of the molecule. One of faces mainly contains planar strips of aromatic and polar residues which may be the carbohydrate binding part. Further aspect are unknown and unique with this CBD such as the other conserved residues which are contained in a groove.  
+
CBD<sub>cipA</sub> is composed of a nine-stranded beta sandwich with a jelly roll topology and binds a calcium ion, which can be seen in Figure 2. It further contains conserved residues exposed on the surface which map into two clear surfaces on each side of the molecule. One of the faces mainly contains planar strips of aromatic and polar residues which may be the carbohydrate binding part. Further aspects are unknown and unique to this CBD such as the other conserved residues which are contained in a groove.
 +
 
 +
<h3>Carbohydrate binding domain specificity</h3>
 +
Since the CBD is from the cellusome of C. thermocellum some research labeled it a cellulose binding domain. However, iGEM19 Linköping noticed that this domain could also bind to different sources of polysaccaride materials. This serves as a domain for iGEM19 Linköpings modular bandage, where the polysaccaride material can be exchanged for other/similar materials and not exclusively cellulose.
  
 
<h3>The choice of carbohydrate binding domain</h3>
 
<h3>The choice of carbohydrate binding domain</h3>
iGEM Linköping 2019 choose CBDcipA due to many other iGEM teams exploring the possibilities of this domain. Our basic design was influenced by iGEM14 Imperial,  iGEM15 Edinburgh and iGEM18 Ecuador. Purification and where to place the fusion protein (N- or C-terminal) was determined by studying the former projects. CBDcipA also originates from a thermophilic bacteria which further increases the domains applications.
+
iGEM Linköping 2019 chose CBD<sub>cipA</sub> due to the fact that many other iGEM teams had explored the possibilities of this domain. Our basic design was influenced by [http://2014.igem.org/Team:Imperial iGEM14 Imperial][http://2015.igem.org/Team:edinburgh iGEM15 Edinburgh] and [http://2018.igem.org/Team:ecuador iGEM18 Ecuador]. Purification and where to place the fusion protein (N- or C-terminal) was determined by studying the former projects. CBD<sub>cipA</sub> also originates from a thermophilic bacteria which further increases the domain's applications.
  
 
+
<br><br>
<br><br><br><br><br><br><br><br>
+
 
<h2>Expression system</h2>
 
<h2>Expression system</h2>
 +
The part has a strong expression with a T7-RNA-polymerase promotor (<partinfo>BBa_I719005</partinfo>), seen in Figure 3,  as well as a 5'-UTR (<partinfo>BBa_K1758100</partinfo>) region which has been shown to further increase expression in <i>Escherichia coli</i> (<i>E. coli</i>) (<partinfo>BBa_K1758106</partinfo>), ([http://www.ncbi.nlm.nih.gov/pubmed/2676996 Olins et al. 1989]), ([http://www.ncbi.nlm.nih.gov/pubmed/23927491 Takahashi et al. 2013]).
  
The part has a very strong expression with a T7-RNA-polymerase promotor (<partinfo>BBa_I719005</partinfo>) as well as a 5'-UTR (<partinfo>BBa_K1758100</partinfo>) region which has been shown to further increase expression in E. coli (<partinfo>BBa_K1758106</partinfo>), ([http://www.ncbi.nlm.nih.gov/pubmed/2676996 Olins et al. 1989]), ([http://www.ncbi.nlm.nih.gov/pubmed/23927491 Takahashi et al. 2013]). Both this part and the part were sfGFP was changed for AsPink (<partinfo>BBa_K3182000</partinfo>) showed great expression.
+
[[File:T--Linkoping_Sweden--expression.png|900px|thumb|center|<b>Figure 3.</b> Benchling screenshot of the expression system. The T7-RNA-polymerase promotor is followed by a T7 g10 leader sequence which enhances the binding to the 16S ribosomal RNA. After the leader sequence a poly A spacer is found, which has been shown to increase translation in vitro. Before the start codon a strong RBS, g10-L, followed by an AT-rich spacer can be seen, which will slightly increase translation of the following gene.]]
  
[[File:T--Linkoping_Sweden--expression.png|900px|thumb|center|<b>Figure B.</b> Benchling screenshot of the expression system. The T7-RNA-polymerase promotor is followed by a T7 g10 leader sequence which enhances the binding to the 16S ribosomal RNA. After the leader sequence a poly A spacer is found, which has been shown to increase translation in vitro. Before the start codon a strong RBS, g10-L, followed by an AT-rich spacer can be seen, which will slightly increase translation of the following gene.]]
+
<h2>Antimicrobial Agent - CHAP(K)</h2>
 
+
Bacteriophage endolysins digest the peptidoglycan wall of bacteria. The LysK is an endolysin targeting gram positive bacteria. It has two catalytical domains known as CHAP (cysteine-and histidine dependent amidohydrolase/peptidase) and a central amidase-2 domain together with a cell binding domain. The CHAP domain (more specifically CHAP C1-C162), which is the truncated part expressed in this year’s LiU iGEM team, still has lytic activity against staphylococcus. The C1 to C162 amino acids are required for full endopeptidase activity. The purpose of the truncation is to increase the antimicrobial effect of CHAP, decrease its risk of immunological response and increase protein yield.  
<h1>Fusion protein bound to the carbohydrate binding domain</h1>
+
INSERT INFO ABOUT AGENT HERE
+
 
<br>
 
<br>
 
<br>
 
<br>
The endolysin is designed to battle the <b>E</b>nterococcus faecium, <b>S</b>taphylococcus aureus, <b>K</b>lebsiella pneumoniae, <b>A</b>cinetobacter baumannii, <b>P</b>seudomonas aeruginosa, <b>E</b>nterobacter spp. family of pathogens (<b>ESKAPE</b>). ESKAPE is a family(ies) of bacteria which has multiple understrains that has evolved resistance to the most commonly used antibiotics.
+
The enzyme is designed to battle the <i><b>E</b>nterococcus faecium</i>, <i><b>S</b>taphylococcus aureus</i>, <i><b>K</b>lebsiella pneumoniae</i>, <i><b>A</b>cinetobacter baumannii</i>, <i><b>P</b>seudomonas aeruginosa</i>, <i><b>E</b>nterobacter spp.</i> family of pathogens (<b>ESKAPE</b>). ESKAPE is a family(s) of bacteria which has multiple substrains that has evolved resistance to the most commonly used antibiotics.
  
<!-- Add more about the biology of this part here
+
<h1>Usage and Biology</h1>
===Usage and Biology===
+
  
<!-- -->
+
The desired function of this construct is that the CBD will allow a more efficient expression of antimicrobial peptides by being a hydrophilic anchor to the bactericidal peptide or enzyme. The CBD can be used for easy purification of the fusion protein and via thrombin cleavage of the linker, yield the peptide or enzyme only. In iGEM19 Linköping's project the thought was to create an antimicrobial bandage by having a polysaccharide bandage with CBD-antimicrobial agents bound to it. When applying the bandage to a patient, the patient's blood (containing thrombin) will release the peptide or enzyme into the wound (thrombin sprays used in hospitals can be used as well) leading to the activation of the peptides/enzymes and enabling them to reach the bacteria, thus eliminating the infecting pathogens.
<span class='h3bb'>Sequence and Features</span>
+
 
 +
<h2>Expression, purification and protease treatment</h2>
 +
 
 +
The antimicrobial agents which iGEM19 Linköping used were all expressed the same way. Early expression experiments showed great promise but with low yields. The early experiments were done with standard <i>E. coli</i> BL21 (DE3) expression, cultures were grown to an optical density at 600 nm (OD<sub>600</sub>) of 0.4-1.0 in varying volumes and induced with 0.5 mM IPTG, and let to express the agents for 16 hours in 18 °C. Harvest of the cells was done at 3500 rpm for 30 minutes.
 +
 
 +
[[File:T--Linkoping Sweden--CHAPrättljus.png|150px|thumb|left|<b>Figure 4</b> 4-20% SDS-gel of insoluble fraction of CBD-CHAP. Lane 1 is a LMW protein ladder by GE healthcare. Lane 2 is the insoluble fraction of CBD-CHAP. The band between 35 and 45 is CHAP(K) which has a molecular weight of 37 kDa.]]
 +
 
 +
<h3>Solubilization and purification</h3>
 +
 
 +
After harvest the cells were re-suspended in phosphate buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl, 10 mM Na<sub>2</sub>HPO<sub>4</sub>, 1.8 mM KH<sub>2</sub>PO<sub>4</sub>) buffer or carbohydrate binding module buffer (CBM-buffer, Tris–HCl pH 7.0, 20 mM NaCl, 5 mM CaCl<sub>2</sub>) and sonicated for 6 minutes, 30 % amplitude and 30 seconds on, 30 seconds off. The sonicated bacteria was then centrifuged at 12000 g for 15 minutes. The soluble fraction was then purified by attaching the CBD-fusion to cellulose. This showed very faint bands on SDS-PAGE analysis. Because of the low yield from the soluble fraction, a detergent (Triton X100, 1 %) was used to re-suspend the lipid-soluble proteins (insoluble fraction).
 +
 
 +
The Triton-X100 1 % fraction was later bound to microcristallin cellulose by Sigma Aldrich. A culture of 1 L <i>E. coli</i> BL21 (DE3) treated as above and lysed in 60 mL CBM-buffer. Half of that amount was then incubated with 5 g of microcristallin cellulose for 2 hours in 4 °C. After binding the CBD-fusion protein to the cellulose, washing was done with either 70 % ethanol, PBS- or CBM-buffer. A volume of 10 mL of each solution was added and incubated with the cellulose for 30 minutes. This step was repeated three times to remove unbound proteins and any residual Triton X100. After washing, elution was done with deionized water. A volume of 10 mL was sufficient to elute some CBD-fusion proteins (room temperature), while others needed higher temperatures (37 °C). This was done in 50 mL tubes under shaking. In hindsight, a column should be used to better track the elution.
 +
 
 +
<h3>Thrombin treatment</h3>
 +
These bound fractions could also be cleaved with thrombin, where 25 units Bovine Thrombin (100 µL) by Sigma Aldrich was added. To this thrombin cleavage buffer (20 mM Tris-HCl, 150 mM NaCl and 2.5 mM CaCl<sub>2</sub>) was also added (500 µL) along with deionized water (4.4 mL). The cellulose bound fraction was discarded and the supernatant, with thrombin and the now unbound antimicrobial agent, was saved for later use. The results from this can be seen in Figure 4.
 +
 
 +
<br><br><br><br><br>
 +
 
 +
<h2>Antimicrobial activity agents in different states</h2>
 +
All experiments below used <i>E. coli</i> BL21 (DE3) or <i>Bacillus Subtilis</i> in concentrations of 10000 CFU/mL. This was done in order to get starting cultures of 0 OD<sub>600</sub>. Using spectrometry to measure the time until the bacteria started growing, instead of showing the killing capability on high optical density cultures, mimicked early stage wounds. This also showed many other interesting things, which can be seen in the results below. One being that an equilibrium settled in lower than for the negative control, meaning even though the antimicrobial agents could not inhibit the growth fully, it was slowed and the stationary phase was reached earlier (Figure 5).
 +
 
 +
<br>
 +
 
 +
<h2>Antimicrobial activity of unbound agents</h2>
 +
[[File:T--Linkoping_Sweden--CHAP123.png|600px|thumb|left|<b>Figure 5</b> <i>A</i>: PlyF307 was tested against an <i>E. coli</i> BL21 (DE3) 0 OD<sub>600</sub> culture. Unfilled boxes is a negative control containing thrombin and thrombin cleavage buffer. Filled boxes indicate CHAP(K). <i>B</i>: CHAP(K) was added to a <i>B. subtilis</i> 0 OD<sub>600</sub> culture. Unfilled boxes indicate negative control containing thrombin and thrombin cleavage buffer. The media used in all wells was low salt LB (0.4 g/L NaCl). The error bars represent the mean ± SD from three independent experiments.]]
  
 +
<h3>Unbound agents</h3>
 +
As a positive control before starting our experiments with the CBD-agent-bandage, the unbound agents were tested for antimicrobial activity when they were not bound to the CBD. The results from this experiment can be seen in Figure 5. The agents were purified and treated with thrombin as stated before. The experimental setup was the same as the earlier experiment but instead of adding water to the negative control, thrombin (0.5 U, final concentration 0.6 µM) and thrombin cleavage buffer (40 µL, 20 mM Tris-HCl, 150 mM NaCl and 2.5 mM CaCl<sub>2</sub>) was added. This was because the agents had thrombin and cleavage buffer with them. This showed to not affect the bacterial growth, but rather increase it due to the added salt due to the cleavage buffer.
  
  

Latest revision as of 14:38, 20 October 2019

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    INCOMPATIBLE WITH RFC[21]
    Illegal BamHI site found at 580
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


Introduction

Figure 1. Mechanism of action for Novosite. The CBDcipA-fusion is attached to a polysaccaride material. By adding thrombin from any source the fusion protein will be cleaved and the C-terminal fusion protein will be released into the solution. By changing the fusion protein to an antimicrobial peptide/enzyme, and using the material as a bandage, the peptide/enzyme can be released into a wound by native human thrombin.

This part consists of a carbohydrate binding domain (CBD) from Clostridium thermocellum (C. thermocellum) cellulose scaffolding protein (CipA). This binding domain is a central part of Clostridium thermocellum's cellusome and has a strong affinity for cellulose. The CBD was fused to another protein using a flexible GS-linker (-GGGGSGGGGS-) in order to attach this complex to a polysaccaride material. A thrombin cleavage site (-LVPRGS-) was added to the end of the linker and its breakage will leave a glycine and serine attached to the N-terminal of the fusion protein. The main mechanism of iGEM19 Linköping's project can be seen in Figure 1.

Protease site and use

The thrombin site was added to enable the ability to release the fusion protein down into skin wounds. Thanks to our integrated human practice we learned that infections span much deeper into wounds that we thought. Simply attaching the CBD-fusion protein to a carbohydrate material would not enable the fusion protein to reach far into the wound. The thrombin site was also chosen because of thrombin's endogenous existence in humans.

Assembly compabilities

An internal BamHI recognition sequence (RS) has been added to enable interchangeable fusion proteins to the CBD. BamHI was chosen because its RS codes for glycine and serine, fitting it to the end of the thrombin site. It is also a cost-effective enzyme and is unaffected by methylated DNA. BamHI is a part of the RFC21 standard.


CBDcipA crystal structure

Figure 2. Crystal structure of CBDcipA with a resolution of 1.75 Å which were solved by [http://www.ncbi.nlm.nih.gov/pmc/PMC452321 Tormo et al. 1989]. PDB code 1NBC. In red from the left, W118, R112, D56, H57 and Y67, thought to be the surface which interacts strongly with polysaccarides.

Important molecular faces

CBDcipA is composed of a nine-stranded beta sandwich with a jelly roll topology and binds a calcium ion, which can be seen in Figure 2. It further contains conserved residues exposed on the surface which map into two clear surfaces on each side of the molecule. One of the faces mainly contains planar strips of aromatic and polar residues which may be the carbohydrate binding part. Further aspects are unknown and unique to this CBD such as the other conserved residues which are contained in a groove.

Carbohydrate binding domain specificity

Since the CBD is from the cellusome of C. thermocellum some research labeled it a cellulose binding domain. However, iGEM19 Linköping noticed that this domain could also bind to different sources of polysaccaride materials. This serves as a domain for iGEM19 Linköpings modular bandage, where the polysaccaride material can be exchanged for other/similar materials and not exclusively cellulose.

The choice of carbohydrate binding domain

iGEM Linköping 2019 chose CBDcipA due to the fact that many other iGEM teams had explored the possibilities of this domain. Our basic design was influenced by [http://2014.igem.org/Team:Imperial iGEM14 Imperial], [http://2015.igem.org/Team:edinburgh iGEM15 Edinburgh] and [http://2018.igem.org/Team:ecuador iGEM18 Ecuador]. Purification and where to place the fusion protein (N- or C-terminal) was determined by studying the former projects. CBDcipA also originates from a thermophilic bacteria which further increases the domain's applications.



Expression system

The part has a strong expression with a T7-RNA-polymerase promotor (BBa_I719005), seen in Figure 3, as well as a 5'-UTR (BBa_K1758100) region which has been shown to further increase expression in Escherichia coli (E. coli) (BBa_K1758106), ([http://www.ncbi.nlm.nih.gov/pubmed/2676996 Olins et al. 1989]), ([http://www.ncbi.nlm.nih.gov/pubmed/23927491 Takahashi et al. 2013]).

Figure 3. Benchling screenshot of the expression system. The T7-RNA-polymerase promotor is followed by a T7 g10 leader sequence which enhances the binding to the 16S ribosomal RNA. After the leader sequence a poly A spacer is found, which has been shown to increase translation in vitro. Before the start codon a strong RBS, g10-L, followed by an AT-rich spacer can be seen, which will slightly increase translation of the following gene.

Antimicrobial Agent - CHAP(K)

Bacteriophage endolysins digest the peptidoglycan wall of bacteria. The LysK is an endolysin targeting gram positive bacteria. It has two catalytical domains known as CHAP (cysteine-and histidine dependent amidohydrolase/peptidase) and a central amidase-2 domain together with a cell binding domain. The CHAP domain (more specifically CHAP C1-C162), which is the truncated part expressed in this year’s LiU iGEM team, still has lytic activity against staphylococcus. The C1 to C162 amino acids are required for full endopeptidase activity. The purpose of the truncation is to increase the antimicrobial effect of CHAP, decrease its risk of immunological response and increase protein yield.

The enzyme is designed to battle the Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp. family of pathogens (ESKAPE). ESKAPE is a family(s) of bacteria which has multiple substrains that has evolved resistance to the most commonly used antibiotics.

Usage and Biology

The desired function of this construct is that the CBD will allow a more efficient expression of antimicrobial peptides by being a hydrophilic anchor to the bactericidal peptide or enzyme. The CBD can be used for easy purification of the fusion protein and via thrombin cleavage of the linker, yield the peptide or enzyme only. In iGEM19 Linköping's project the thought was to create an antimicrobial bandage by having a polysaccharide bandage with CBD-antimicrobial agents bound to it. When applying the bandage to a patient, the patient's blood (containing thrombin) will release the peptide or enzyme into the wound (thrombin sprays used in hospitals can be used as well) leading to the activation of the peptides/enzymes and enabling them to reach the bacteria, thus eliminating the infecting pathogens.

Expression, purification and protease treatment

The antimicrobial agents which iGEM19 Linköping used were all expressed the same way. Early expression experiments showed great promise but with low yields. The early experiments were done with standard E. coli BL21 (DE3) expression, cultures were grown to an optical density at 600 nm (OD600) of 0.4-1.0 in varying volumes and induced with 0.5 mM IPTG, and let to express the agents for 16 hours in 18 °C. Harvest of the cells was done at 3500 rpm for 30 minutes.

Figure 4 4-20% SDS-gel of insoluble fraction of CBD-CHAP. Lane 1 is a LMW protein ladder by GE healthcare. Lane 2 is the insoluble fraction of CBD-CHAP. The band between 35 and 45 is CHAP(K) which has a molecular weight of 37 kDa.

Solubilization and purification

After harvest the cells were re-suspended in phosphate buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4) buffer or carbohydrate binding module buffer (CBM-buffer, Tris–HCl pH 7.0, 20 mM NaCl, 5 mM CaCl2) and sonicated for 6 minutes, 30 % amplitude and 30 seconds on, 30 seconds off. The sonicated bacteria was then centrifuged at 12000 g for 15 minutes. The soluble fraction was then purified by attaching the CBD-fusion to cellulose. This showed very faint bands on SDS-PAGE analysis. Because of the low yield from the soluble fraction, a detergent (Triton X100, 1 %) was used to re-suspend the lipid-soluble proteins (insoluble fraction).

The Triton-X100 1 % fraction was later bound to microcristallin cellulose by Sigma Aldrich. A culture of 1 L E. coli BL21 (DE3) treated as above and lysed in 60 mL CBM-buffer. Half of that amount was then incubated with 5 g of microcristallin cellulose for 2 hours in 4 °C. After binding the CBD-fusion protein to the cellulose, washing was done with either 70 % ethanol, PBS- or CBM-buffer. A volume of 10 mL of each solution was added and incubated with the cellulose for 30 minutes. This step was repeated three times to remove unbound proteins and any residual Triton X100. After washing, elution was done with deionized water. A volume of 10 mL was sufficient to elute some CBD-fusion proteins (room temperature), while others needed higher temperatures (37 °C). This was done in 50 mL tubes under shaking. In hindsight, a column should be used to better track the elution.

Thrombin treatment

These bound fractions could also be cleaved with thrombin, where 25 units Bovine Thrombin (100 µL) by Sigma Aldrich was added. To this thrombin cleavage buffer (20 mM Tris-HCl, 150 mM NaCl and 2.5 mM CaCl2) was also added (500 µL) along with deionized water (4.4 mL). The cellulose bound fraction was discarded and the supernatant, with thrombin and the now unbound antimicrobial agent, was saved for later use. The results from this can be seen in Figure 4.






Antimicrobial activity agents in different states

All experiments below used E. coli BL21 (DE3) or Bacillus Subtilis in concentrations of 10000 CFU/mL. This was done in order to get starting cultures of 0 OD600. Using spectrometry to measure the time until the bacteria started growing, instead of showing the killing capability on high optical density cultures, mimicked early stage wounds. This also showed many other interesting things, which can be seen in the results below. One being that an equilibrium settled in lower than for the negative control, meaning even though the antimicrobial agents could not inhibit the growth fully, it was slowed and the stationary phase was reached earlier (Figure 5).


Antimicrobial activity of unbound agents

Figure 5 A: PlyF307 was tested against an E. coli BL21 (DE3) 0 OD600 culture. Unfilled boxes is a negative control containing thrombin and thrombin cleavage buffer. Filled boxes indicate CHAP(K). B: CHAP(K) was added to a B. subtilis 0 OD600 culture. Unfilled boxes indicate negative control containing thrombin and thrombin cleavage buffer. The media used in all wells was low salt LB (0.4 g/L NaCl). The error bars represent the mean ± SD from three independent experiments.

Unbound agents

As a positive control before starting our experiments with the CBD-agent-bandage, the unbound agents were tested for antimicrobial activity when they were not bound to the CBD. The results from this experiment can be seen in Figure 5. The agents were purified and treated with thrombin as stated before. The experimental setup was the same as the earlier experiment but instead of adding water to the negative control, thrombin (0.5 U, final concentration 0.6 µM) and thrombin cleavage buffer (40 µL, 20 mM Tris-HCl, 150 mM NaCl and 2.5 mM CaCl2) was added. This was because the agents had thrombin and cleavage buffer with them. This showed to not affect the bacterial growth, but rather increase it due to the added salt due to the cleavage buffer.